HealthVerity Releases its Provider Diversity Index 2023


Enhancements to the new edition support pharma and CROs to increase diversity in clinical trials, as well as align recruitment with disease incidence

HealthVerity has released its Provider Diversity Index (PDI) 2023 edition, which includes new enhancements such as age range, gender, income range, payer type (commercial, Medicare or Medicaid) and diagnosis.

First introduced in 2020, this nationally-syndicated report synchronizes medical, pharmacy and social determinants of health data from a large data ecosystem to calculate the racial diversity of patients for over 1 million physician practices, all in a HIPAA-compliant manner. The HealthVerity PDI is being used by pharma sponsors to identify clinical trial site investigators and to more effectively characterize and recruit patient populations that better reflect the diversity mix of diagnosed patients.

Alzheimer's is an example of a condition that disproportionately affects minorities. According to the Alzheimer's Association, 19% of Black/African American and 14% of Hispanic/Latino adults age 65 and older have Alzheimer's, compared to 10% of White/Caucasian seniors In contrast, participants in a 2020 clinical trial for an Alzheimer's medication were 86% White/Caucasian. Its PDI, says the company, could leverage diagnosis in a HIPAA-compliant manner to highlight physicians treating broader cohorts of minority patients whose recruitment could yield more effective clinical trial results.

"These statistics demonstrate how critical it is that researchers be able to work on clinical trials with physicians who have better access to patient populations representative of their particular study," said Andrew Kress, CEO of HealthVerity, in a press release.

Reference: HealthVerity releases the Provider Diversity Index 2023 edition to increase diversity in clinical trials. PHILADELPHIA, July 18, 2023. PRNewswire.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.